Last reviewed · How we verify

local mometasone furoate treatment

University Hospital, Ghent · FDA-approved active Small molecule

local mometasone furoate treatment is a Topical corticosteroid Small molecule drug developed by University Hospital, Ghent. It is currently FDA-approved for Inflammatory skin conditions (e.g., eczema, dermatitis, psoriasis), Allergic skin reactions, Pruritus and other localized inflammatory dermatological conditions.

Mometasone furoate is a topical corticosteroid that suppresses local inflammatory and immune responses by binding to glucocorticoid receptors.

Mometasone furoate is a topical corticosteroid that suppresses local inflammatory and immune responses by binding to glucocorticoid receptors. Used for Inflammatory skin conditions (e.g., eczema, dermatitis, psoriasis), Allergic skin reactions, Pruritus and other localized inflammatory dermatological conditions.

At a glance

Generic namelocal mometasone furoate treatment
SponsorUniversity Hospital, Ghent
Drug classTopical corticosteroid
TargetGlucocorticoid receptor
ModalitySmall molecule
Therapeutic areaDermatology / Immunology
PhaseFDA-approved

Mechanism of action

Mometasone furoate is a potent synthetic corticosteroid that reduces inflammation, itching, and immune-mediated reactions at the site of application. It works by activating glucocorticoid receptors in immune cells and epithelial tissues, leading to decreased production of inflammatory mediators and reduced recruitment of immune cells. When applied locally, it provides anti-inflammatory and antipruritic effects with minimal systemic absorption.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about local mometasone furoate treatment

What is local mometasone furoate treatment?

local mometasone furoate treatment is a Topical corticosteroid drug developed by University Hospital, Ghent, indicated for Inflammatory skin conditions (e.g., eczema, dermatitis, psoriasis), Allergic skin reactions, Pruritus and other localized inflammatory dermatological conditions.

How does local mometasone furoate treatment work?

Mometasone furoate is a topical corticosteroid that suppresses local inflammatory and immune responses by binding to glucocorticoid receptors.

What is local mometasone furoate treatment used for?

local mometasone furoate treatment is indicated for Inflammatory skin conditions (e.g., eczema, dermatitis, psoriasis), Allergic skin reactions, Pruritus and other localized inflammatory dermatological conditions.

Who makes local mometasone furoate treatment?

local mometasone furoate treatment is developed and marketed by University Hospital, Ghent (see full University Hospital, Ghent pipeline at /company/university-hospital-ghent).

What drug class is local mometasone furoate treatment in?

local mometasone furoate treatment belongs to the Topical corticosteroid class. See all Topical corticosteroid drugs at /class/topical-corticosteroid.

What development phase is local mometasone furoate treatment in?

local mometasone furoate treatment is FDA-approved (marketed).

What are the side effects of local mometasone furoate treatment?

Common side effects of local mometasone furoate treatment include Local skin atrophy, Skin irritation or burning, Folliculitis, Hypopigmentation.

What does local mometasone furoate treatment target?

local mometasone furoate treatment targets Glucocorticoid receptor and is a Topical corticosteroid.

Related